Active Ingredient History
Alovudine (fluorothymidine) is an antiviral agent which was being developed by Medivir. It was discontinued after a Phase II trial in 2005 due to toxicity. It is a DNA polymerase inhibitor. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Anus Neoplasms (Phase 2)
Astrocytoma (Phase 1/Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 1)
Breast Neoplasms (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Verrucous (Phase 1)
Endometrial Neoplasms (Phase 2)
Genital Neoplasms, Female (Early Phase 1)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1/Phase 2)
Graft vs Host Disease (Early Phase 1)
Head and Neck Neoplasms (Phase 2/Phase 3)
HIV Infections (Phase 2)
Laryngeal Neoplasms (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Melanoma (Phase 2)
Mouth Neoplasms (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neurofibromatoses (Phase 1)
Neurofibrosarcoma (Phase 1)
Oropharyngeal Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 2)
Salivary Gland Neoplasms (Phase 1)
Sarcoma (Early Phase 1)
Sarcoma, Ewing (Phase 1)
Stomach Neoplasms (Phase 2)
Thymus Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue